All News


The trouble with Framework Programmes

A quietly published review has criticised FP6 as too bureaucratic, and for not reaching out to the private sector. But are these failings being perpetuated in FP7?

Will Roche get what it paid for?

Beyond its blockbuster drugs Genentech has a commodity rare in a large company – an entrepreneurial culture. Can Roche preserve this?